A detailed history of Morgan Stanley transactions in Achilles Therapeutics PLC stock. As of the latest transaction made, Morgan Stanley holds 16,431 shares of ACHL stock, worth $16,923. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,431
Previous 8,931 83.98%
Holding current value
$16,923
Previous $7,000 128.57%
% of portfolio
0.0%
Previous 0.0%

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.7 - $1.04 $5,250 - $7,800
7,500 Added 83.98%
16,431 $16,000
Q2 2024

Oct 17, 2024

SELL
$0.75 - $1.25 $6,952 - $11,587
-9,270 Reduced 50.93%
8,931 $7,000
Q2 2024

Aug 14, 2024

SELL
$0.75 - $1.25 $6,952 - $11,587
-9,270 Reduced 50.93%
8,931 $7,000
Q1 2024

Oct 17, 2024

BUY
$0.82 - $1.57 $7,601 - $14,553
9,270 Added 103.8%
18,201 $22,000
Q1 2024

Aug 16, 2024

BUY
$0.82 - $1.57 $14,908 - $28,544
18,181 Added 90905.0%
18,201 $22,000
Q1 2024

May 15, 2024

BUY
$0.82 - $1.57 $14,908 - $28,544
18,181 Added 90905.0%
18,201 $22,000
Q4 2023

Aug 16, 2024

SELL
$0.78 - $0.96 $6,950 - $8,554
-8,911 Reduced 99.78%
20 $0
Q4 2023

Feb 13, 2024

SELL
$0.78 - $0.96 $39,000 - $48,000
-50,000 Reduced 99.96%
20 $0
Q3 2023

Nov 15, 2023

SELL
$0.84 - $1.11 $19,095 - $25,233
-22,733 Reduced 31.25%
50,020 $45,000
Q2 2023

Aug 14, 2023

SELL
$0.82 - $1.09 $172,942 - $229,887
-210,906 Reduced 74.35%
72,753 $69,000
Q1 2023

May 15, 2023

BUY
$0.84 - $1.26 $238,273 - $357,410
283,659 New
283,659 $272,000
Q3 2022

Nov 14, 2022

BUY
$2.26 - $3.38 $1,850 - $2,768
819 Added 12.93%
7,155 $16,000
Q2 2022

Oct 27, 2022

BUY
$1.96 - $3.04 $225 - $349
115 Added 1.85%
6,336 $16,000
Q2 2022

Aug 15, 2022

BUY
$1.96 - $3.04 $225 - $349
115 Added 1.85%
6,336 $16,000
Q1 2022

Oct 27, 2022

SELL
$2.8 - $5.23 $322 - $601
-115 Reduced 1.82%
6,221 $18,000
Q1 2022

May 13, 2022

SELL
$2.8 - $5.23 $358 - $669
-128 Reduced 2.02%
6,221 $18,000
Q4 2021

Feb 14, 2022

BUY
$4.22 - $8.86 $26,792 - $56,252
6,349 New
6,349 $32,000

Others Institutions Holding ACHL

About Achilles Therapeutics plc


  • Ticker ACHL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,774,000
  • Market Cap $42M
  • Description
  • Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...
More about ACHL
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.